Christopher T Ritchlin1, James G Krueger. 1. aUniversity of Rochester Medical Center, RochesterbMilstein Medical Research Program, Rockefeller University, New York, New York, USA.
Abstract
PURPOSE OF REVIEW: Over the last several years, novel immunologic pathways pivotal in the development of the pathobiology of psoriasis and psoriatic arthritis (PsA) have been revealed. These discoveries catalyzed a search for new treatment targets resulting in many new therapies that are now available for patients with psoriatic disease. RECENT FINDINGS: Helper T cells that secrete interleukin-17 (TH17) along with CD8+ cells, innate lymphocyte cells, and gamma delta T cells are important in the pathogenesis of psoriasis and PsA. Recently, agents that target interleukin-17, the interleukin-17 receptor, and interleukin-23 (antip19) have been approved or are in clinical trials. Apremilast, a new oral agent, was approved for the treatment of psoriasis and PsA. SUMMARY: Secukinumab, an interleukin-17A antibody, has been approved for treatment of psoriasis and PsA in the United States. It is effective with a good safety profile. Ixekizumab, another anti-interleukin-17A antibody, is currently in clinical trials and brodalumab, an interleukin-17 receptor antagonist, was removed from clinical trials because of safety concerns despite demonstrated efficacy in psoriasis and PsA. Targeting interleukin-23 with antibodies to p19 is another approach with encouraging results in psoriasis. Apremilast, an oral agent, approved to treat psoriasis and PsA demonstrates moderate efficacy with an excellent safety record. The role of tofacitinib in psoriatic disease remains to be determined pending a safety review in psoriasis and completion of PsA trials.
PURPOSE OF REVIEW: Over the last several years, novel immunologic pathways pivotal in the development of the pathobiology of psoriasis and psoriatic arthritis (PsA) have been revealed. These discoveries catalyzed a search for new treatment targets resulting in many new therapies that are now available for patients with psoriatic disease. RECENT FINDINGS:Helper T cells that secrete interleukin-17 (TH17) along with CD8+ cells, innate lymphocyte cells, and gamma delta T cells are important in the pathogenesis of psoriasis and PsA. Recently, agents that target interleukin-17, the interleukin-17 receptor, and interleukin-23 (antip19) have been approved or are in clinical trials. Apremilast, a new oral agent, was approved for the treatment of psoriasis and PsA. SUMMARY:Secukinumab, an interleukin-17A antibody, has been approved for treatment of psoriasis and PsA in the United States. It is effective with a good safety profile. Ixekizumab, another anti-interleukin-17A antibody, is currently in clinical trials and brodalumab, an interleukin-17 receptor antagonist, was removed from clinical trials because of safety concerns despite demonstrated efficacy in psoriasis and PsA. Targeting interleukin-23 with antibodies to p19 is another approach with encouraging results in psoriasis. Apremilast, an oral agent, approved to treat psoriasis and PsA demonstrates moderate efficacy with an excellent safety record. The role of tofacitinib in psoriatic disease remains to be determined pending a safety review in psoriasis and completion of PsA trials.
Authors: Kenneth B Gordon; Kristina Callis Duffin; Robert Bissonnette; Jörg C Prinz; Yasmine Wasfi; Shu Li; Yaung-Kaung Shen; Philippe Szapary; Bruce Randazzo; Kristian Reich Journal: N Engl J Med Date: 2015-07-09 Impact factor: 91.245
Authors: K Papp; D Thaçi; K Reich; E Riedl; R G Langley; J G Krueger; A B Gottlieb; H Nakagawa; E P Bowman; A Mehta; Q Li; Y Zhou; R Shames Journal: Br J Dermatol Date: 2015-10-15 Impact factor: 9.302
Authors: Philip J Mease; Iain B McInnes; Bruce Kirkham; Arthur Kavanaugh; Proton Rahman; Désirée van der Heijde; Robert Landewé; Peter Nash; Luminita Pricop; Jiacheng Yuan; Hanno B Richards; Shephard Mpofu Journal: N Engl J Med Date: 2015-10 Impact factor: 91.245
Authors: Kim Papp; Kristian Reich; Craig L Leonardi; Leon Kircik; Sergio Chimenti; Richard G B Langley; ChiaChi Hu; Randall M Stevens; Robert M Day; Kenneth B Gordon; Neil J Korman; Christopher E M Griffiths Journal: J Am Acad Dermatol Date: 2015-07 Impact factor: 11.527
Authors: James G Krueger; Scott Fretzin; Mayte Suárez-Fariñas; Patrick A Haslett; Krista M Phipps; Gregory S Cameron; Juliet McColm; Artemis Katcherian; Inna Cueto; Traci White; Subhashis Banerjee; Robert W Hoffman Journal: J Allergy Clin Immunol Date: 2012-06-05 Impact factor: 10.793
Authors: Arthur Kavanaugh; Philip J Mease; Juan J Gomez-Reino; Adewale O Adebajo; Jürgen Wollenhaupt; Dafna D Gladman; Eric Lespessailles; Stephen Hall; Marla Hochfeld; ChiaChi Hu; Douglas Hough; Randall M Stevens; Georg Schett Journal: Ann Rheum Dis Date: 2014-03-04 Impact factor: 19.103
Authors: Oscar Vegas; Brian Poligone; Paul Blackcloud; Elaine S Gilmore; JoAnne VanBuskirk; Christopher T Ritchlin; Alice P Pentland; Scott A Walter; Yasmine Nousari; Francisco Tausk Journal: Brain Behav Immun Date: 2017-11-07 Impact factor: 7.217
Authors: Lu Yang; Melania H Fanok; Aranzazu Mediero-Munoz; Laura K Fogli; Carmen Corciulo; Shahla Abdollahi; Bruce N Cronstein; Jose U Scher; Sergei B Koralov Journal: Arthritis Rheumatol Date: 2018-04-18 Impact factor: 10.995
Authors: Adrienn Katalin Poór; Fanni Rencz; Valentin Brodszky; László Gulácsi; Zsuzsanna Beretzky; Bernadett Hidvégi; Péter Holló; Sarolta Kárpáti; Márta Péntek Journal: Qual Life Res Date: 2017-09-05 Impact factor: 4.147
Authors: Alexandra Zanin-Zhorov; Jonathan M Weiss; Alissa Trzeciak; Wei Chen; Jingya Zhang; Melanie S Nyuydzefe; Carmen Arencibia; Seetharam Polimera; Olivier Schueller; Judilyn Fuentes-Duculan; Kathleen M Bonifacio; Norma Kunjravia; Inna Cueto; Jennifer Soung; Roy M Fleischmann; Alan Kivitz; Mark Lebwohl; Margarita Nunez; Johnnie Woodson; Shondra L Smith; Robert F West; Mark Berger; James G Krueger; John L Ryan; Samuel D Waksal Journal: J Immunol Date: 2017-04-07 Impact factor: 5.422
Authors: Mika Yamanaka-Takaichi; Soha Ghanian; David A Katzka; Rochelle R Torgerson; Afsaneh Alavi Journal: Am J Clin Dermatol Date: 2022-04-15 Impact factor: 6.233